Evidence map›Paper›PMID 25034337›Full record

ArticleJournal of theoretical biology2014

Simulations suggest pharmacological methods for rescuing long-term potentiation.

Paul Smolen, Douglas A Baxter, John H Byrne

Open access · greenAbstract read
In one paragraph

Article in Journal of theoretical biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Paul SmolenLaboratory of Origin: Department of Neurobiology and Anatomy, W. M. Keck Center for the Neurobiology of Learning and Memory, The University of Texas Medical School at Houston, Houston, TX 77030, United States. Electronic address: Paul.D.Smolen@uth.tmc.edu.
Douglas A BaxterLaboratory of Origin: Department of Neurobiology and Anatomy, W. M. Keck Center for the Neurobiology of Learning and Memory, The University of Texas Medical School at Houston, Houston, TX 77030, United States.
John H ByrneLaboratory of Origin: Department of Neurobiology and Anatomy, W. M. Keck Center for the Neurobiology of Learning and Memory, The University of Texas Medical School at Houston, Houston, TX 77030, United States.
The University of Texas Health Science Center at Houston · US

Funding

Modeling Gene Regulation Essential for Long-Term PlasticityR01NS073974 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI BYRNE, JOHN H · 2011 to 2015
$1.5M
NINDS NIH HHS R01 NS073974NINDS NIH HHS R01NS073974
6 · The paper itself

Abstract

Congenital cognitive dysfunctions are frequently due to deficits in molecular pathways that underlie the induction or maintenance of synaptic plasticity. For example, Rubinstein-Taybi syndrome (RTS) is due to a mutation in cbp, encoding the histone acetyltransferase CREB-binding protein (CBP). CBP is a transcriptional co-activator for CREB, and induction of CREB-dependent transcription plays a key role in long-term memory (LTM). In animal models of RTS, mutations of cbp impair LTM and late-phase long-term potentiation (LTP). As a step toward exploring plausible intervention strategies to rescue the deficits in LTP, we extended our previous model of LTP induction to describe histone acetylation and simulated LTP impairment due to cbp mutation. Plausible drug effects were simulated by model parameter changes, and many increased LTP. However no parameter variation consistent with a effect of a known drug class fully restored LTP. Thus we examined paired parameter variations consistent with effects of known drugs. A pair that simulated the effects of a phosphodiesterase inhibitor (slowing cAMP degradation) concurrent with a deacetylase inhibitor (prolonging histone acetylation) restored normal LTP. Importantly these paired parameter changes did not alter basal synaptic weight. A pair that simulated the effects of a phosphodiesterase inhibitor and an acetyltransferase activator was similarly effective. For both pairs strong additive synergism was present. The effect of the combination was greater than the summed effect of the separate parameter changes. These results suggest that promoting histone acetylation while simultaneously slowing the degradation of cAMP may constitute a promising strategy for restoring deficits in LTP that may be associated with learning deficits in RTS. More generally these results illustrate how the strategy of combining modeling and empirical studies may provide insights into the design of effective therapies for improving long-term synaptic plasticity and learning associated with cognitive disorders.

Indexed as

Models, BiologicalComputer SimulationDrug SynergismHistone Deacetylase InhibitorsHumansLong-Term PotentiationMetabolic Networks and PathwaysMutationNeuronal PlasticityPeptide FragmentsPhosphodiesterase InhibitorsRubinstein-Taybi SyndromeSialoglycoproteinsbone sialoprotein (35-62), humanHistone Deacetylase InhibitorsPeptide FragmentsPhosphodiesterase InhibitorsSialoglycoproteinsCognitive disordersCombination therapyDrug synergismLong-term memoryRubinstein–Taybi syndrome

Identifiers

PMID25034337
PMCPMC4162763
OpenAlexW2039226234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.